ProCE Banner Activity

Phase II Trial of Ipilimumab ± Talimogene Laherparepvec in Unresected Stage IIIB-IV Melanoma

Slideset Download
Conference Coverage
Combination treatment doubled ORR vs ipilimumab alone with no unexpected toxicity.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology